A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib

Document Details

Document Type
Pub Defense Publication
Publication Date
Feb 01, 2020
Source ID
10.1016/j.ejca.2019.12.001

Entities

People

  • Antoine Italiano
  • Axel Le Cesne
  • Christine Chevreau
  • Corinne Delcambre
  • Emilie Decoupigny
  • Emmanuelle Bompas
  • Esma Saada-bouzid
  • François Bertucci
  • Isabelle Ray-coquard
  • Jean-yves Blay
  • Jennifer Wallet
  • Loïc Chaigneau
  • Lucie Laroche
  • Marie Vanseymortier
  • Marie-cécile Le Deley
  • Nicolas Penel
  • Olivier Mir
  • Sebastien Salas
  • Sophie Taieb
  • Thomas Brodowicz

Organizations

  • ARIAD Pharmaceuticals
  • Amgen
  • Bayer HealthCare
  • Bayer USA
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Institut National du Cancer
  • Novartis
  • Office of Nuclear Physics
  • Pfizer
  • PharmaMar